Phathom Pharmaceuticals has shot up ~50% in Friday trading after the disclosure that a member of its board made a significant ...

Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases ... and in our other filings with the SEC. The forward-looking statements are applicable ...

Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University Sc ...

Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.

Expected to complement Castle's current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development ...

Previse is a gastrointestinal health company with a primary focus on chronic acid reflux related diseases ... and in our other filings with the SEC. The forward-looking statements are applicable ...

M.D., Sky Ridge Heartburn and Reflux Treatment Center and Institute of Esophageal and Reflux Surgery Session Type: Poster Session Session Title: Pancreatic and Esophageal Diseases Session #: 7105 ...

M.D., Sky Ridge Heartburn and Reflux Treatment Center and Institute of Esophageal and Reflux Surgery Date & Time: Monday, May 5, 12:15-12:45 p.m. About Digestive Disease Week ® (DDW) Digestive ...

May 1, 2025Phathom Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.31 EPS, expectations were $-1.06. Operator: Hello and welcome to the Phathom Pharmaceuticals’ First ...

FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial ...